Philips announces late-breaking results from iMODERN trial at TCT conference

Philips (PHG) announced late-breaking results from the iMODERN trial at the Transcatheter Cardiovascular Therapeutics 2025 conference. The study compared immediate versus delayed treatment of additional narrowed arteries in heart attack patients to determine whether treating all blockages in one procedure is as safe and effective as waiting for a follow-up procedure. The study compared immediate versus deferred treatment of additional narrowed arteries in heart attack patients to determine whether treating all blockages in a single procedure is superior to waiting for a follow-up procedure – a key question, since many patients have multiple diseased arteries and the optimal timing for complete treatment remains uncertain. The new findings show that patients can safely have additional arteries treated immediately during the first procedure to treat the acute event, rather than during a later second intervention. By confirming the safety of extending Class I, Level A-recommended iFR to non-stable patients, the results offer physicians the opportunity to complete treatment in one session, without compromising long-term outcomes. The iMODERN trial is the largest study to date testing iFR in the acute heart attack setting, expanding the evidence base for a tool already strongly recommended in stable patients. The study’s main endpoint combined three outcomes: death, another heart attack, or hospitalization for heart failure over three years. After three years of follow-up, the trial found no significant difference in major outcomes – including death, repeat heart attack, or hospitalization for heart failure – between the two approaches. By confirming that both approaches are backed by solid evidence, the trial offers patients more certainty and more personalized care. In related findings presented at the same conference, the ILIAS ANOCA study further demonstrated the value of physiology-guided decision-making – this time in patients with angina and no obstructive coronary arteries. The ILIAS ANOCA study evaluated the impact of coronary function testing in patients whose coronary arteries appear unobstructed on angiography but who continue to experience angina. Conducted across five cardiac centers in the Netherlands and Germany, the investigator-initiated, randomized, blinded-arm controlled trial compared standard care with CFT-guided medical therapy using Philips Doppler FloWire and FloMap systems. The study found that ad-hoc CFT followed by tailored therapy significantly improved patient-reported angina symptoms and quality of life at six months, with a mean 9.4-point gain in the Seattle Angina Questionnaire summary score. There were no procedure-related complications or major adverse cardiac events. These results confirm and extend the earlier CorMiCA findings, supporting CFT as a Class I, Level A recommendation in ANOCA patients and demonstrating the potential of Philips Doppler technology to guide individualized treatment strategies safely and effectively. The 12-month results presented on October 26 demonstrate the sustained benefits of CFT-guided care.